Seattle Genetics, Inc. (SGEN) Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at American Society of Clinical Oncology Annual Meeting
6/3/2013 7:12:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted ongoing clinical development programs for ADCETRIS (brentuximab vedotin) in frontline Hodgkin lymphoma (HL) and mature T-cell lymphoma (MTCL) and progress with collaborator antibody-drug conjugate (ADC) programs that were presented at the 49th Annual Meeting of the American Society of Clinical Oncology being held May 31 – June 4, 2013, in Chicago, IL.
Help employers find you! Check out all the jobs and post your resume.
comments powered by